受试者中至少50%无冠心病病史，随访大于等于12个月的随机对照试验入选本次分析。

Randomized controlled trials with a study population with at least 50% of the subjects having no history of coronary heart disease and 12 or more months of follow-up were included.

youdao

一级终点为无中风的生存，死亡和优于药物治疗，目前已入选了14例患者。

The primary endpoint in this arm is survival without stroke or death and superiority to medical therapy. This trial arm has enrolled 14 patients to date.

youdao